IMAC Holdings, Inc. (IMAC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IMAC Holdings, Inc. (IMAC) trades at $1.01 with AI Score 38/100 (Grade D). IMAC Holdings, Inc. operates a chain of outpatient medical clinics providing regenerative and minimally invasive procedures. Market cap: $33.08M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for IMAC: IMAC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMAC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMAC: 1/1 perspectives are bearish.
How is this calculated? →IMAC Holdings, Inc. (IMAC) Healthcare & Pipeline Overview
IMAC Holdings, Inc. owns and manages outpatient medical clinics offering regenerative and minimally invasive treatments for musculoskeletal conditions and pain management. Operating across multiple states, IMAC distinguishes itself through a focus on regenerative medicine within the fragmented medical care facilities sector, but faces challenges with profitability.
What Is the Investment Thesis for IMAC?
Investing in IMAC Holdings, Inc. presents a high-risk, high-reward scenario. The company operates in the growing regenerative medicine market, offering potential for significant revenue growth if it can successfully scale its operations and achieve profitability. Key value drivers include expanding its clinic network, increasing patient volume, and improving operational efficiency. However, the company's negative profit margin of -42693.2% and gross margin of -1838.8% raise concerns about its financial viability. Upcoming catalysts include potential partnerships with healthcare providers and expansion into new geographic markets. Investors should carefully consider the company's financial challenges and competitive landscape before investing.
Based on FMP financials and quantitative analysis
IMAC Key Highlights
- Market capitalization of $33.08M, indicating a small-cap company with potential for growth but also higher volatility.
- Negative P/E ratio of -0.02, reflecting the company's current lack of profitability.
- Profit Margin of -42693.2%, signaling significant challenges in achieving profitability.
- Gross Margin of -1838.8%, indicating that the direct costs of providing services exceed revenue.
- Beta of -0.89, suggesting that the stock is less volatile than the overall market.
Who Are IMAC's Competitors?
IMAC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| ALR AlerisLife Inc. | $1.32 | +0.00% | $44.18M | 39 |
| GRCE Grace Therapeutics, Inc. | $2.54 | +6.96% | $41.25M | 50 |
| IRD Opus Genetics, Inc. | $4.21 | -0.59% | $347.19M | — |
| ISO IsoPlexis Corporation | $0.76 | +0.00% | $30.28M | 43 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMAC's Key Strengths?
- Specialized focus on regenerative medicine.
- Network of outpatient medical clinics.
- Experienced medical professionals.
- Proprietary treatment protocols.
What Are IMAC's Weaknesses?
- Negative profit margin.
- High operating expenses.
- Limited brand recognition.
- Small market capitalization.
What Could Drive IMAC Stock Higher?
- Potential partnerships with healthcare providers to expand referral network.
- Expansion into new geographic markets with high demand for regenerative medicine.
- Development and commercialization of new regenerative therapies.
- Increased adoption of regenerative medicine by patients and physicians.
What Are the Key Risks for IMAC?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established healthcare providers and specialized clinics.
- Regulatory scrutiny and changes in healthcare regulations.
- Reimbursement challenges from insurance companies.
- Negative profit margin and high operating expenses.
- Dependence on key personnel and medical professionals.
What Are the Growth Opportunities for IMAC?
- Expansion into New Geographic Markets: IMAC has the opportunity to expand its footprint by opening new clinics in underserved markets. Focusing on regions with a high concentration of active individuals and an aging population could drive patient volume. A phased expansion approach, starting with one or two new locations per year, would allow the company to manage its capital expenditures and ensure operational efficiency. The total addressable market for regenerative medicine is projected to reach $55 billion by 2028, providing a significant runway for growth.
- Strategic Partnerships with Healthcare Providers: Partnering with hospitals, physician groups, and other healthcare providers can expand IMAC's referral network and patient base. Collaborating with established players in the healthcare industry can also enhance IMAC's credibility and market reach. These partnerships could involve joint marketing initiatives, shared facilities, or integrated care pathways. This strategy could lead to a 20% increase in patient referrals within the first year of implementation.
- Development of New Regenerative Therapies: Investing in research and development to develop new regenerative therapies can differentiate IMAC from its competitors and attract patients seeking cutting-edge treatments. This could involve collaborating with universities and research institutions to explore new applications of regenerative medicine. Successful development and commercialization of new therapies could significantly increase IMAC's revenue and market share. The global regenerative medicine market is expected to grow at a CAGR of 18% over the next five years.
- Enhancement of Digital Marketing and Telehealth Capabilities: Investing in digital marketing and telehealth capabilities can improve patient access and engagement. This could involve developing a user-friendly website, implementing online appointment scheduling, and offering virtual consultations. Telehealth can also expand IMAC's reach to patients in remote areas. A comprehensive digital marketing strategy could increase patient inquiries by 30% within the first year.
- Focus on Value-Based Care Models: Transitioning to value-based care models can improve patient outcomes and reduce healthcare costs. This involves focusing on providing high-quality care that is tailored to the individual needs of each patient. Value-based care models can also improve patient satisfaction and loyalty. By demonstrating improved patient outcomes and reduced costs, IMAC can attract more patients and negotiate favorable reimbursement rates with payers. This approach aligns with the growing trend towards value-based care in the healthcare industry.
What Opportunities Does IMAC Have?
- Expansion into new geographic markets.
- Strategic partnerships with healthcare providers.
- Development of new regenerative therapies.
- Increased adoption of regenerative medicine.
What Threats Does IMAC Face?
- Competition from established healthcare providers.
- Regulatory scrutiny.
- Reimbursement challenges.
- Economic downturn.
What Are IMAC's Competitive Advantages?
- Specialized focus on regenerative medicine.
- Network of outpatient medical clinics in multiple states.
- Proprietary treatment protocols and techniques.
- Established relationships with referring physicians.
What Does IMAC Do?
Founded in 2000 and headquartered in Brentwood, Tennessee, IMAC Holdings, Inc. owns, manages, and subleases a network of medical centers focused on regenerative medicine and minimally invasive procedures. The company's core business revolves around providing outpatient care for patients suffering from sports-related injuries, ligament and tendon damage, soft tissue conditions, and chronic pain, including back, knee, and joint pain. IMAC's clinics offer a range of treatments, including regenerative therapies, orthopedic procedures, physical therapy, spinal decompression, and chiropractic manipulation. IMAC's business model centers around owning or managing outpatient medical clinics. These clinics are strategically located in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. The company aims to provide innovative medical advancements and care regeneration services to its patients. IMAC's focus on regenerative medicine positions it within a growing segment of the healthcare industry that seeks to leverage the body's natural healing processes to address a variety of conditions. However, the company's financial performance, as indicated by its negative profit and gross margins, presents a significant challenge to its long-term sustainability.
What Products and Services Does IMAC Offer?
- Owns and manages outpatient medical clinics.
- Provides regenerative medicine therapies.
- Offers orthopedic procedures.
- Performs minimally invasive procedures.
- Treats sports-related injuries.
- Addresses ligament and tendon damage.
- Manages soft tissue conditions.
- Provides pain management services for back, knee, and joint pain.
How Does IMAC Make Money?
- Generates revenue through patient fees for medical procedures and therapies.
- Manages and subleases medical clinic space.
- Focuses on outpatient care to reduce costs.
- Offers a range of services, including regenerative medicine, orthopedics, and pain management.
What Industry Does IMAC Operate In?
IMAC Holdings operates within the medical care facilities industry, a fragmented sector characterized by a mix of large hospital systems, specialized clinics, and independent practices. The industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology, particularly in regenerative medicine. IMAC's focus on regenerative and minimally invasive procedures positions it within a niche market that is gaining traction. However, the company faces competition from established healthcare providers and other specialized clinics. The industry is also subject to regulatory scrutiny and reimbursement challenges.
Who Are IMAC's Key Customers?
- Individuals with sports-related injuries.
- Patients suffering from ligament and tendon damage.
- Individuals with soft tissue conditions.
- Patients experiencing chronic pain, including back, knee, and joint pain.
How IMAC Holdings, Inc. Is Valued
IMAC Holdings, Inc. carries a market capitalization of $33.08M, placing it in the micro-cap category. Relative to its peer group, IMAC's quantitative score of 38/100 is below the peer average of 50/100.
ROE 73%Key Financial Metrics
Return on equity for IMAC Holdings, Inc. stands at 72.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
IMAC Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Net buyingInsider Activity
The most recent 11 insider filings for IMAC Holdings, Inc. break down as 4 sales and 7 purchases. On net that is roughly 191K shares acquired (about $53K) — insiders putting money in tends to read as conviction.
IMAC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized focus on regenerative medicine.
- Network of outpatient medical clinics.
- Experienced medical professionals.
- Proprietary treatment protocols.
Bear Case
- Negative profit margin.
- High operating expenses.
- Limited brand recognition.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
IMAC Latest News
No recent news available for IMAC.
IMAC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMAC.
Price Targets
Wall Street price target analysis for IMAC.
IMAC MoonshotScore
What does this score mean?
The MoonshotScore rates IMAC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeffrey S. Ervin
CEO
Jeffrey S. Ervin serves as the CEO of IMAC Holdings, Inc. His background includes experience in healthcare management and operations. He is responsible for overseeing the company's strategic direction, financial performance, and day-to-day operations. He manages a team of 154 employees, ensuring the efficient delivery of medical services across the company's network of clinics. His leadership is crucial in navigating the challenges and opportunities in the regenerative medicine market.
Track Record: Since becoming CEO, Jeffrey S. Ervin has focused on expanding IMAC's clinic network and improving operational efficiency. He has also overseen the development of new regenerative therapies and the implementation of digital marketing strategies. Under his leadership, IMAC has faced challenges related to profitability and market competition. He continues to work on improving the company's financial performance and market position.
IMAC Healthcare Stock FAQ
What does IMAC Holdings, Inc. do?
IMAC Holdings, Inc. operates a chain of outpatient medical clinics that specialize in regenerative medicine, orthopedic procedures, and minimally invasive treatments. The company focuses on treating patients with sports-related injuries, ligament and tendon damage, soft tissue conditions, and chronic pain, including back, knee, and joint pain. IMAC's clinics offer a range of services, including regenerative therapies, physical therapy, spinal decompression, and chiropractic manipulation. The company aims to provide innovative medical advancements and care regeneration services to its patients across multiple states.
What are the main risks for IMAC?
IMAC faces several key risks, including competition from established healthcare providers, regulatory scrutiny, and reimbursement challenges. The company's negative profit margin and high operating expenses also pose significant risks to its financial viability. Dependence on key personnel and medical professionals is another risk factor. Additionally, changes in healthcare regulations and economic downturns could negatively impact the company's performance. Investors should carefully consider these risks before investing in IMAC.
What are the key factors to evaluate for IMAC?
IMAC Holdings, Inc. (IMAC) holds an AI score of 38/100 (low). Not financial advice.
How frequently does IMAC data refresh on this page?
IMAC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IMAC's recent stock price performance?
IMAC Holdings, Inc. (IMAC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on regenerative medicine. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMAC overvalued or undervalued right now?
Valuing IMAC Holdings, Inc. (IMAC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IMAC?
Before investing in IMAC Holdings, Inc. (IMAC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding IMAC to a portfolio?
Key strength of IMAC Holdings, Inc. (IMAC): Specialized focus on regenerative medicine. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide further insights.
- The company's financial performance is subject to change based on market conditions and operational factors.